Search

Displaying results 2691 - 2700 of 10000 in total
  1. Drug

    Delgocitinib

    go.drugbank.com/drugs/DB16133
    ApprovedInvestigational

    [A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508] … After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024.

  2. Drug

    Foslevodopa

    go.drugbank.com/drugs/DB16683
    Approved

    Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Advanced Parkinson's Disea...

    Mixtures: Produodopa 240 mg/ml + 12 mg/ml Infusionslösung
  3. Drug

    Regadenoson

    go.drugbank.com/drugs/DB06213
    ApprovedInvestigational

    Manufactured by Astellas and FDA approved April 10, 2008.

  4. Drug

    Foscarbidopa

    go.drugbank.com/drugs/DB16171
    Approved

    Foscarbidopa is under investigation in clinical trial NCT04379050 (Extension Study to Evaluate Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Parkinson's Disea...

    Mixtures: Produodopa 240 mg/ml + 12 mg/ml Infusionslösung
  5. Drug

    Kappadione

    go.drugbank.com/drugs/DB09332
    Approved

    It has been found to have carcinogenic potential in mammalian cells as well as cytotoxic properties [L1544]. … Kappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is

  6. Drug

    Stiripentol

    go.drugbank.com/drugs/DB09118
    ApprovedInvestigational

    [A250825] However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs

    Synonyms: 1-(1,3-Benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-olCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Substrates
  7. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Odesivimab (REGN 3471), [Maftivimab] (REGN 3479), and [Atoltivimab] (REGN 3470) in equimolar proportions

  8. Drug

    Potassium carbonate

    go.drugbank.com/drugs/DB13977
    Approved

    It can be made as the product of potassium hydroxide's absorbent reaction with carbon dioxide. It presents a large capacity to absorb moisture.

    Mixtures: Buffered Vitamin C Powder With Ca Mg and K, Vit C W Calc-mag and Potass Powder
  9. Drug

    Chlormerodrin

    go.drugbank.com/drugs/DB00534
    ApprovedWithdrawn

    Chlormerodrin is a mercurial compound with toxic side effects that was previously used as a diuretic. The radiolabeled form has been used as a diagnostic and research tool. … It is no longer used and has been replaced with new classes of diuretic drugs.

  10. Target

    Beta-lactamase OXA-10

    go.drugbank.com/bio_entities/BE0001274
    TargetEnzymePseudomonas aeruginosa

    Hydrolyzes both carbenicillin and oxacillin.

    Polypeptides: Beta-lactamase OXA-10